Abstract
During evolution, pathogens have evolved strategies to counteract key cellular restriction mechanisms in order to efficiently invade target cells and fulfill essential steps of their replication cycle. Human Immunodeficiency Virus-1 and some Simian counterparts express a small multifunctional protein, Vpu, which influences viral replication. By acting as a multifunctional adapter, Vpu enhances viral particle release and infectivity. Therefore Vpu, an accessory protein, contributes to pathogenesis while avoiding superinfection. These effects rely mainly on the ability of Vpu to target the host proteins CD4 and BST-2/tetherin. Indeed, Vpu downregulates the cell surface expression of these receptors and subsequently induces their proteolysis via a mechanism involving a β -TrCP-containing E3 ubiquitin ligase complex. In this review, we will detail recent research aimed at elucidating the mechanism of Vpu-mediated CD4 and BST-2/tetherin downregulation and degradation as well as their subsequent consequences on viral pathogenesis.
Keywords: BST-2/tetherin, CD4, Human Immunodeficiency Virus-1 (HIV-1), lysosome, proteasome, SCFbTrCP E3 ubiquitin ligase, Ubiquitination, Viral Protein U (Vpu), degradation, proteolysis
Current HIV Research
Title:β -TrCP Dependency of HIV-1 Vpu-Induced Downregulation of CD4 and BST-2/Tetherin
Volume: 10 Issue: 4
Author(s): Fabien P. Blanchet, J. P. Mitchell and Vincent Piguet
Affiliation:
Keywords: BST-2/tetherin, CD4, Human Immunodeficiency Virus-1 (HIV-1), lysosome, proteasome, SCFbTrCP E3 ubiquitin ligase, Ubiquitination, Viral Protein U (Vpu), degradation, proteolysis
Abstract: During evolution, pathogens have evolved strategies to counteract key cellular restriction mechanisms in order to efficiently invade target cells and fulfill essential steps of their replication cycle. Human Immunodeficiency Virus-1 and some Simian counterparts express a small multifunctional protein, Vpu, which influences viral replication. By acting as a multifunctional adapter, Vpu enhances viral particle release and infectivity. Therefore Vpu, an accessory protein, contributes to pathogenesis while avoiding superinfection. These effects rely mainly on the ability of Vpu to target the host proteins CD4 and BST-2/tetherin. Indeed, Vpu downregulates the cell surface expression of these receptors and subsequently induces their proteolysis via a mechanism involving a β -TrCP-containing E3 ubiquitin ligase complex. In this review, we will detail recent research aimed at elucidating the mechanism of Vpu-mediated CD4 and BST-2/tetherin downregulation and degradation as well as their subsequent consequences on viral pathogenesis.
Export Options
About this article
Cite this article as:
P. Blanchet Fabien, P. Mitchell J. and Piguet Vincent, β -TrCP Dependency of HIV-1 Vpu-Induced Downregulation of CD4 and BST-2/Tetherin, Current HIV Research 2012; 10 (4) . https://dx.doi.org/10.2174/157016212800792441
DOI https://dx.doi.org/10.2174/157016212800792441 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genomic Instability and Cancer
Current Molecular Medicine <sup>177</sup>Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay
Current Radiopharmaceuticals Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry Cell Cycle Dependent Regulation of Intracellular Calcium Concentration in Vascular Smooth Muscle Cells: A Potential Target for Drug Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders The Wnt Pathway: Emerging Anticancer Strategies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Viral Origins of Human Cancer
Current Medicinal Chemistry When Neighbors Talk: Colon Cancer Cell Invasion and Tumor Microenvironment Myofibroblasts
Current Drug Targets VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design Bortezomib – First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Transcriptional Analysis of JAK/STAT Signaling in Glioblastoma Multiforme
Current Pharmacogenomics and Personalized Medicine Pharmacogenetic Applications of the Post Genomic Era
Current Pharmaceutical Biotechnology Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery Development of Scaffolds for Vascular Tissue Engineering: Biomaterial Mediated Neovascularization
Current Stem Cell Research & Therapy Autophagy Inhibition in Childhood Nephroblastoma and the Therapeutic Significance
Current Cancer Drug Targets Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids
Current Topics in Medicinal Chemistry Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Current Topics in Medicinal Chemistry The Safety and Efficacy of Parathyroid Hormone (PTH) as a Biological Response Modifier for the Enhancement of Bone Regeneration
Current Drug Safety Colon Targeted Liposomal Systems (CTLS): Theranostic Potential
Current Molecular Medicine Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents